Guidelines for the management of a Malignant Hyperthermia Crisis

Successful treatment of a Malignant Hyperthermia (MH) crisis depends on early diagnosis and aggressive treatment. The onset of a reaction can be within minutes of induction or may be more insidious. Previous uneventful anaesthesia does not exclude MH. The steps below are intended as an aide memoire. Presentation may vary and treatment should be modified accordingly. Know where the dantrolene is stored in your theatre. Treatment can be optimised by teamwork.

Call for help

**Diagnosis - consider MH if:**
1. Unexplained, unexpected increase in end-tidal CO₂ together with
2. Unexplained, unexpected tachycardia together with
3. Unexplained, unexpected increased in oxygen consumption

Masseter muscle spasm, and especially more generalised muscle rigidity after suxamethonium, indicate a high risk of MH susceptibility but are usually self-limiting.

**Take measures to halt the MH process:**
1. Remove trigger drugs, turn off vaporisers, use high fresh gas flows (oxygen), use a new, clean non-rebreathing circuit, hyperventilate. Maintain anaesthesia with intravenous agents such as propofol until surgery completed.
2. Dantrolene; give 2-3 mg.kg⁻¹ i.v. initially and then 1 mg.kg⁻¹ PRN.
3. Use active body cooling but avoid vasoconstriction. Convert active warming devices to active cooling, give cold intravenous infusions, cold peritoneal lavage, extracorporeal heat exchange.

**Monitor:**
ECG, SpO₂, end-tidal CO₂, invasive arterial BP, CVP, core and peripheral temperature, urine output and pH, arterial blood gases, potassium, haematocrit, platelets, clotting indices, creatine kinase (peaks at 12-24h).

**Treat the effects of MH:**
1. Hypoxaemia and acidosis: 100% O₂, hyperventilate, sodium bicarbonate.
2. Hyperkalaemia: sodium bicarbonate, glucose & insulin, i.v. calcium chloride (if in extremis).
3. Myoglobinemia: forced alkaline diuresis (aim for urine output >3 ml.kg⁻¹.h⁻¹, urine pH >7.0).
5. Cardiac arrhythmias: procainamide, magnesium, amiodarone (avoid calcium channel blockers - interaction with dantrolene).

**ICU management:**
2. Assess for renal failure and compartment syndrome.
3. Give further dantrolene as necessary (recurdescence can occur for up to 24h).
4. Consider other diagnoses, e.g. sepsis, phaeochromocytoma, myopathy.

**Late management:**
1. Counsel patient and/or family regarding implications of MH.
2. Refer patient to MH Unit.

This poster is produced by the AAGBI and is endorsed by the British MH Association. © The Association of Anaesthetists of Great Britain & Ireland 2009